Renascience

Renascience Net Margin

The Net Profit Margin of Renascience (4889.T) as of Nov 19, 2026 is -439.47 %. In the previous year, Net Profit Margin was 85.48 % — a change of -614.12% (lower).

Net Margin

-439.47 %

YoY

-614.12%

Last updated:

Net Profit Margin of Renascience is 2026 -439.47 % . Net Profit Margin of Renascience was 2025 85.48 % . It decreases by -614.12% lower compared to the previous year.

For Renascience, the net margin of -439.5% is down versus -246.8% a few years ago.

The Renascience Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2020
-255.56 JPY
Jan 1, 2021
-47.69 JPY
Jan 1, 2022
-182.51 JPY
Jan 1, 2023
-333.98 JPY
Jan 1, 2024
-133.05 JPY
Jan 1, 2025
85.48 JPY
Jan 1, 2026
-439.47 JPY
The Renascience Net Margin history
YEARNet MarginYoY
-439.47 %-614.12%
85.48 %-164.25%
-133.05 %-60.16%
-333.98 %+82.99%
-182.51 %+282.70%
-47.69 %-81.34%
-255.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Net Profit Margin of Renascience is -439.47 % in 2026.

Net Profit Margin of Renascience changed from 85.48 % to -439.47 %, representing a -614.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Renascience since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Renascience with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Renascience

All Key Metrics — Renascience